Skip to content

Exploration of the Therapeutic Value and Underlying Mechanisms of Natural Plant-Derived Medicines in Regulating Metabolic Disorders During the Menopausal Transition

Exploration of the Therapeutic Value and Underlying Mechanisms of Natural Plant-Derived Medicines in Regulating Metabolic Disorders During the Menopausal Transition

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128834
Enrollment
Unknown
Registered
2026-07-27
Start date
2026-07-30
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perimenopausal syndrome associated with metabolic disorders

Interventions

Sangzhi Alkaloids Group:Sangzhi Alkaloids Tablets
Menopausal Hormone Therapy Group:Femoston 2/10
Combination Therapy Group:Sangzhi Alkaloids Plus Menopausal Hormone Therapy

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1.Female aged 40–55 years; 2.Amenorrhea for 6 months to 5 years; 3.Diagnosis of perimenopausal syndrome; 4.Modified Kupperman score >= 10; 5.Written informed consent provided;

Exclusion criteria

Exclusion criteria: 1. Uterine fibroids >=3 cm in diameter; 2. Endometriosis with significant clinical symptoms or signs; 3. Diagnosed diabetes mellitus or hypertension; 4. History of thromboembolic disease or predisposition to thrombosis; 5. Epilepsy, asthma, or hyperprolactinemia; 6. First-degree family history of breast cancer; 7. ALT or AST >2 times the upper limit of normal, or serum creatinine >1.5 times the upper limit of normal; 8. Uncontrolled hypertension (SBP >=160 mmHg or DBP >=100 mmHg); 9. Severe cardiovascular, respiratory, gastrointestinal, neurological, immunological, or hematological diseases; 10. Use of estrogen preparations or menopause-related health products within the previous 3 months; 11. Endometrial thickness >=0.5 cm after drug withdrawal or abnormal cervical cytology (except inflammation); 12. Known allergy to the study medications; 13. Participation in another clinical trial within 1 month prior to enrollment; 14. History of alcohol or substance abuse/dependence within the previous 3 months; 15. Any other condition considered unsuitable for participation by the investigator.

Design outcomes

Primary

MeasureTime frame
Modified Kupperman Index;

Secondary

MeasureTime frame
Safety Outcomes;Follicle-Stimulating Hormone and Estradiol;Fasting Blood Glucose;Menopause-Specific Quality of Life Questionnaire;

Countries

China

Contacts

Public ContactSun Aijun

Peking Union Medical College Hospital

847542123@qq.com+86 10 69155728

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026